CLPBY Hold Rating Maintained by Deutsche Bank, May 2026

Deutsche Bank kept its Hold rating on Coloplast A/S (CLPBY) on May 18, 2026, but trimmed its price target. The analyst firm lowered the target to DKK 460 from DKK 495, signaling caution on the medical device maker’s near-term prospects. CLPBY trades at $6.39, down from its 52-week high of $10.03. The CLPBY Hold rating reflects mixed sentiment across the analyst community, with one Buy, three Holds, and one Sell rating currently active.

Deutsche Bank Maintains CLPBY Hold Rating with Lower Price Target

Deutsche Bank’s decision to maintain its Hold rating on CLPBY while cutting the price target reflects growing caution about the company’s valuation and near-term momentum. The analyst firm lowered the price target to DKK 460 from DKK 495, a reduction of approximately 7.3 percent. This adjustment suggests the bank sees limited upside from current levels.

Coloplast operates in the medical devices sector, focusing on intimate healthcare products across three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. The company’s market cap stands at $14.2 billion, making it a significant player in healthcare. The CLPBY Hold rating aligns with the broader analyst consensus, which includes one Buy recommendation against three Holds and one Sell.

Financial Metrics Show Mixed Signals for CLPBY Investors

Coloplast’s valuation metrics paint a complex picture. The stock trades at a price-to-earnings ratio of 44.05, well above typical healthcare device averages, while the price-to-sales ratio sits at 3.44. Return on equity stands at 14 percent, indicating reasonable profitability, but the debt-to-equity ratio of 1.89 signals elevated leverage. Free cash flow per share reached $2.68, providing some cushion for dividends and operations.

Meyka AI rates CLPBY with a grade of B, reflecting a Neutral recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The company’s operating margin of 28 percent demonstrates solid operational efficiency despite recent headwinds.

Stock Performance and Technical Outlook for CLPBY

CLPBY has struggled significantly over the past year, declining 33.7 percent. The stock trades above its 50-day average of $6.64 and below its 200-day average of $8.32, suggesting intermediate weakness. Recent price action shows volatility, with the stock trading between $6.29 and $6.42 in the current session.

Technical indicators reveal mixed momentum. The Relative Strength Index (RSI) sits at 45.21, indicating neither overbought nor oversold conditions. The Money Flow Index of 65.25 suggests some buying pressure, but the MACD remains negative at -0.11. CLPBY faces resistance at the 200-day moving average, which could limit near-term gains if the stock attempts a recovery.

Analyst Consensus and Growth Outlook for CLPBY

The analyst community remains divided on CLPBY’s prospects. With one Buy, three Holds, and one Sell rating, the consensus leans cautious. Deutsche Bank’s price target reduction reinforces concerns about valuation and growth sustainability. Revenue growth of 3.1 percent year-over-year appears modest for a healthcare device company, while net income declined 28 percent, raising profitability questions.

Operating cash flow surged 140 percent, and free cash flow jumped 234 percent, suggesting improved cash generation. However, earnings per share fell 28.2 percent, indicating that cash improvements haven’t translated to bottom-line strength. The CLPBY Hold rating reflects this disconnect between operational cash flow and reported earnings.

Final Thoughts

Deutsche Bank’s maintained Hold rating on CLPBY, paired with a lower price target, signals caution about Coloplast’s near-term trajectory. While the company generates solid cash flow and maintains reasonable profitability, elevated valuation multiples and declining earnings create headwinds. The CLPBY Hold rating reflects broader analyst skepticism, with the consensus split between one Buy and one Sell against three Holds. Investors should monitor upcoming earnings in August 2026 for signs of stabilization. The stock’s technical position remains weak, trading below its 200-day average, suggesting further downside risk before any meaningful recovery emerges.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.